NX-001 / NephRx - LARVOL DELTA

Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol-Induced Liver Injury Mediated by Gut-Liver Axis Modulation. (PubMed, Mol Nutr Food Res) - "Integrated microbiome-metabolome analysis revealed a negative correlation between Lactobacillus and toxic bile acids, and a positive correlation between Bifidobacterium and anti-inflammatory metabolites. These findings demonstrate that NXU0014 mitigates liver injury by modulating gut-liver axis metabolic interactions, highlighting its potential as a novel probiotic-based therapy for alcoholic liver disease."

Journal • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • TJP1

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Nuformix Technologies Limited; Active, not recruiting ➔ Completed

Clinical • Trial completion

"Nuformix $NFX Commences NXP001 Clinical Trial https://t.co/dPybh2BJrv" (@BiotechRadar)

Clinical

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Nuformix Technologies Limited

Clinical • New P1 trial

"Nuformix $NFX MHRA approval to commence NXP001 Human Pharmacokinetics https://t.co/jLM9COGUT9" (@BiotechRadar)

PK/PD data